Brief: Newron announces encouraging preliminary results of its phase IIa study with Evenamide in patients with schizophrenia
03/01/2017 16:31
Jan 3 (Reuters) - Newron Pharmaceuticals Spa NWRN.S
* Newron announces encouraging preliminary results of its
phase IIa study with Evenamide in patients with schizophrenia
Source text for Eikon: ID:nTENpmrnwa
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study